CytoSorbents Corporation (NASDAQ: CTSO) is a leader in critical care immunotherapy, specializing in blood purification, and its flagship product, CytoSorb®, is approved in the European Union with distribution in 58 countries around the world, as an extracorporeal cytokine adsorber designed to reduce the "cytokine storm" or "cytokine release syndrome" that could otherwise cause massive inflammation, organ failure and death in common critical illnesses, according to the company’s website (see here: www.cytosorb.com).
SNNLive caught up with Phillip P. Chan, MD, PhD, CEO of CytoSorbents Corporation at the MicroCap Rodeo 2019 in Austin, TX, and discuss the following topics:
- Overview of CytoSorbents Corporation
- Update since our last interview (click here)
- Size of target market for CytoSorb®
- Intellectual property
- Business model
- Value catalysts for rest of 2019, going into 2020
- CytoSorb® progress in the US: clinical development
For more information about CytoSorbents Corporation, please visit: www.cytosorb.com
The interview may contain forward looking statements about CytoSorbents Corporation. See CytoSorbents Corporation's periodic filings with the Securities and Exchange Commission for more complete information.
Please read our full disclosure here.